{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:15:31Z","timestamp":1772151331803,"version":"3.50.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,4]]},"DOI":"10.7759\/cureus.96107","type":"journal-article","created":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T04:45:50Z","timestamp":1762317950000},"source":"Crossref","is-referenced-by-count":1,"title":["A Case Report: Ertapenem-Induced Encephalopathy"],"prefix":"10.7759","author":[{"given":"Russell Boonchai","family":"Lim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baoxian","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron Zijie","family":"Meng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.4103\/indianjpsychiatry.indianjpsychiatry_21_22","article-title":"Management of medication-induced psychiatric disorders","volume":"64","author":"Raju NN","year":"2022","unstructured":"Raju NN, Kumar KS, Nihal G. Management of medication-induced psychiatric disorders. Indian J Psychiatry. 2022, 64:S281-91. 10.4103\/indianjpsychiatry.indianjpsychiatry_21_22","journal-title":"Indian J Psychiatry"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.4065\/81.10.1361","article-title":"Psychiatric adverse effects of corticosteroids","volume":"81","author":"Warrington TP","year":"2006","unstructured":"Warrington TP, Bostwick JM. Psychiatric adverse effects of corticosteroids. Mayo Clin Proc. 2006, 81:1361-7. 10.4065\/81.10.1361","journal-title":"Mayo Clin Proc"},{"key":"ref3","article-title":"Anticholinergic effects of medication in elderly patients","volume":"62 Suppl 21","author":"Tune LE","year":"2001","unstructured":"Tune LE. Anticholinergic effects of medication in elderly patients. J Clin Psychiatry. 2001, 62 Suppl 21:11-4.","journal-title":"J Clin Psychiatry"},{"key":"ref4","article-title":"Opioid complications and side effects","volume":"11","author":"Benyamin R","year":"2008","unstructured":"Benyamin R, Trescot AM, Datta S, et al.. Opioid complications and side effects. Pain Phys. 2008, 11:105-20.","journal-title":"Pain Phys"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1159\/000139363","article-title":"Benzodiazepine side effects: role of pharmacokinetics and pharmacodynamics","volume":"51","author":"Vgontzas AN","year":"1995","unstructured":"Vgontzas AN, Kales A, Bixler EO. Benzodiazepine side effects: role of pharmacokinetics and pharmacodynamics. Pharmacology. 1995, 51:205-23. 10.1159\/000139363","journal-title":"Pharmacology"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/joim.13543","article-title":"Antibiotics and mental health: the good, the bad and the ugly","volume":"292","author":"Dinan K","year":"2022","unstructured":"Dinan K, Dinan T. Antibiotics and mental health: the good, the bad and the ugly. J Intern Med. 2022, 292:858-69. 10.1111\/joim.13543","journal-title":"J Intern Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.54565","article-title":"Fluoroquinolones: neurological complications and side effects in clinical practice","volume":"16","author":"Anwar AI","year":"2024","unstructured":"Anwar AI, Lu L, Plaisance CJ, et al.. Fluoroquinolones: neurological complications and side effects in clinical practice. Cureus. 2024, 16:e54565. 10.7759\/cureus.54565","journal-title":"Cureus"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1186\/1752-1947-5-63","article-title":"Metronidazole-induced encephalopathy in a patient with infectious colitis: a case report","volume":"5","author":"Kim H","year":"2011","unstructured":"Kim H, Kim YW, Kim SR, Park IS, Jo KW. Metronidazole-induced encephalopathy in a patient with infectious colitis: a case report. J Med Case Rep. 2011, 5:63. 10.1186\/1752-1947-5-63","journal-title":"J Med Case Rep"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-199615020-00001","article-title":"Neurotoxicity of carbapenem antibacterials","volume":"15","author":"Norrby SR","year":"1996","unstructured":"Norrby SR. Neurotoxicity of carbapenem antibacterials. Drug Saf. 1996, 15:87-90. 10.2165\/00002018-199615020-00001","journal-title":"Drug Saf"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2011.03991.x","article-title":"Neurotoxic effects associated with antibiotic use: management considerations","volume":"72","author":"Grill MF","year":"2011","unstructured":"Grill MF, Maganti RK. Neurotoxic effects associated with antibiotic use: management considerations. Br J Clin Pharmacol. 2011, 72:381-93. 10.1111\/j.1365-2125.2011.03991.x","journal-title":"Br J Clin Pharmacol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1592\/phco.31.4.408","article-title":"Epileptogenic potential of carbapenem agents: mechanism of action, seizure rates, and clinical considerations","volume":"31","author":"Miller AD","year":"2011","unstructured":"Miller AD, Ball AM, Bookstaver PB, Dornblaser EK, Bennett CL. Epileptogenic potential of carbapenem agents: mechanism of action, seizure rates, and clinical considerations. Pharmacotherapy. 2011, 31:408-23. 10.1592\/phco.31.4.408","journal-title":"Pharmacotherapy"},{"key":"ref12","article-title":"Inferring ADR causality by predicting the Naranjo Score from clinical notes","volume":"2020","author":"Rawat BP","year":"2021","unstructured":"Rawat BP, Jagannatha A, Liu F, Yu H. Inferring ADR causality by predicting the Naranjo Score from clinical notes. AMIA Annu Symp Proc. 2021, 2020:1041-9.","journal-title":"AMIA Annu Symp Proc"},{"key":"ref13","article-title":"INVANZ\u00ae (Ertapenem for Injection) for Intravenous (IV) or Intramuscular (IM) Use: Highlights of Prescribing Information","year":"2001","unstructured":"INVANZ\u00ae (Ertapenem for Injection) for Intravenous (IV) or Intramuscular (IM) Use. Highlights of Prescribing Information. Merck Sharp & Dohme Corp., Whitehouse Station; 2001."},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S406852","article-title":"Ertapenem-induced neurotoxicity: a literature review of clinical characteristics and treatment outcomes","volume":"16","author":"Wang C","year":"2023","unstructured":"Wang C, Zhou Y, Zhou Y, Ye C. Ertapenem-induced neurotoxicity: a literature review of clinical characteristics and treatment outcomes. Infect Drug Resist. 2023, 16:3649-58. 10.2147\/IDR.S406852","journal-title":"Infect Drug Resist"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1177\/2324709616689376","article-title":"Ertapenem-induced encephalopathy in a patient with normal renal function","volume":"5","author":"Sutton SS","year":"2017","unstructured":"Sutton SS, Jumper M, Cook S, Edun B, Wyatt MD. Ertapenem-induced encephalopathy in a patient with normal renal function. J Investig Med High Impact Case Rep. 2017, 5:2324709616689376. 10.1177\/2324709616689376","journal-title":"J Investig Med High Impact Case Rep"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/s40199-021-00425-5","article-title":"Probable ertapenem-induced encephalopathy; case report and suggested alternatives for chronic prostatitis","volume":"30","author":"Fern\u00e1ndez-Rubio B","year":"2022","unstructured":"Fern\u00e1ndez-Rubio B, Luque-M\u00e1rquez R, Gil-Navarro MV. Probable ertapenem-induced encephalopathy; case report and suggested alternatives for chronic prostatitis. Daru. 2022, 30:159-63. 10.1007\/s40199-021-00425-5","journal-title":"Daru"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2023-256876","article-title":"Ertapenem-induced encephalopathy in a patient with liver abscess and acute kidney injury","volume":"17","author":"Farooq S","year":"2024","unstructured":"Farooq S, Acosta A. Ertapenem-induced encephalopathy in a patient with liver abscess and acute kidney injury. BMJ Case Rep. 2024, 17:10.1136\/bcr-2023-256876","journal-title":"BMJ Case Rep"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1P528","article-title":"Central nervous system toxicity associated with ertapenem use","volume":"45","author":"Duquaine S","year":"2011","unstructured":"Duquaine S, Kitchell E, Tate T, Tannen RC, Wickremasinghe IM. Central nervous system toxicity associated with ertapenem use. Ann Pharmacother. 2011, 45:e6. 10.1345\/aph.1P528","journal-title":"Ann Pharmacother"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2019-231875","article-title":"Ertapenem-induced encephalopathy","volume":"13","author":"Adams R","year":"2020","unstructured":"Adams R, Chopra P, Miranda R, Calderon A. Ertapenem-induced encephalopathy. BMJ Case Rep. 2020, 13:10.1136\/bcr-2019-231875","journal-title":"BMJ Case Rep"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.52732","article-title":"A case of ertapenem-induced delirium","volume":"16","author":"Aquilina M","year":"2024","unstructured":"Aquilina M, Galdes N, Spiteri N. A case of ertapenem-induced delirium. Cureus. 2024, 16:e52732. 10.7759\/cureus.52732","journal-title":"Cureus"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/342995-a-case-report-ertapenem-induced-encephalopathy","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T04:45:55Z","timestamp":1762317955000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/342995-a-case-report-ertapenem-induced-encephalopathy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,4]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.96107","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11,4]]}}}